reports
Immunocore to report fourth quarter and full year 2025 financial resul...
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year e...
Transgene Announces Financial Calendar for 2026
Transgene Announces Financial Calendar for 2026 Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial reporting and Annual shareholders’ meeting dates for 2026: March 24, 2026: 2025 Fiscal Year Results April 29, 2026: First Quarter 2026 Financial Results May 13, 2026: Annual Shareholders’ Meeting September 24, 2026: First Half 2026 Financial Results November 9, 2026: ...
Transgene présente son calendrier de communication financière pour 202...
Transgene présente son calendrier de communication financière pour 2026 Strasbourg (France), le 4 février 2026, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce aujourd'hui son calendrier de communication financière pour 2026 et la date de son Assemblée générale annuelle : 24 mars 2026 : Résultats annuels de l’exercice 2025 29 avril 2026 : Résultats financiers du premier trimestre 2026 13 mai 2026 : Assembl...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing ...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the C...
Immunocore announces R&D leadership evolution
Immunocore announces R&D leadership evolution Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 30 January 2026) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that Dr. David Berman, E...
BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin
BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin Mainz, Deutschland, 28. Januar 2026 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Kylie Jimenez mit Wirkung zum 1. März 2026 zur Personalvorständin (Chief People Officer, „CPO“) ernannt hat. Die Ernennung folgt konsequent der strategischen Ausrichtung BioNTechs, um sich bis 2030 zu einem Onkologieunternehmen mit mehreren zugelassenen Produkten zu entwickeln, und unterstreicht die Bedeutung der globalen, hochqualifizierten Belegschaft des Unternehmens, um dieses Ziel z...
BioNTech Announces Appointment of Kylie Jimenez to Management Board as...
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1, 2026. The appointment is in line with BioNTech’s strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jim...
Transgene Further Strengthens Scientific Advisory Board with Appointme...
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific advisors to its Scientific Advisory Board, Prof. Antoine Italiano, MD, PhD, and Prof. Ignacio Melero, MD, PhD, further strengthening its scientific leadership. “Antoine and Ignacio are world leaders...
Transgene renforce son comité scientifique avec l’arrivée d’Antoine It...
Transgene renforce son comité scientifique avec l’arrivée d’Antoine Italiano et Ignacio Melero, deux experts renommés en immunothérapie du cancer Strasbourg, France, 23 janvier 2026, 8 h 00 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce la nomination de deux nouveaux experts au sein de son comité scientifique, le Prof Antoine Italiano, MD, PhD, et le Prof Ignacio Melero, MD, PhD, renforçant ainsi son leadership scientifique. « Reconnus internationalement pour leur leader...
- Oliver Metzger
- Stephane Houri
WCH WACKER CHEMIE AG
G1A GEA GROUP AG
CBK COMMERZBANK AG
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
WTB WHITBREAD PLC
LXS LANXESS AG
MRK MERCK KGAA
BOSS HUGO BOSS AG
BAS BASF SE
CAP CAPGEMINI SE
AIXA AIXTRON SE
SQN SWISSQUOTE GROUP HOLDING AG
KGX KION GROUP AG
BC BRUNELLO CUCINELLI S.P.A.
FTG111 FLATEXDEGIRO AG
SIE SIEMENS AG
SHL SIEMENS HEALTHINEERS AG
MRNA MODERNA INC.
BNTX BIONTECH SE
ENR SIEMENS ENERGY AG
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ZAB ZABKA GROUP
PFSE PFISTERER HOLDING SE
- Oliver Metzger
- Stephane Houri
WCH WACKER CHEMIE AG
G1A GEA GROUP AG
CBK COMMERZBANK AG
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
WTB WHITBREAD PLC
LXS LANXESS AG
MRK MERCK KGAA
BOSS HUGO BOSS AG
BAS BASF SE
CAP CAPGEMINI SE
AIXA AIXTRON SE
SQN SWISSQUOTE GROUP HOLDING AG
KGX KION GROUP AG
BC BRUNELLO CUCINELLI S.P.A.
FTG111 FLATEXDEGIRO AG
SIE SIEMENS AG
SHL SIEMENS HEALTHINEERS AG
MRNA MODERNA INC.
BNTX BIONTECH SE
ENR SIEMENS ENERGY AG
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ZAB ZABKA GROUP
PFSE PFISTERER HOLDING SE
- Jacob Mekhael
Autolus Aucatzyl launch success, FY25 preliminary revenue in line with...
Yesterday before US market opens, Autolus announced preliminary unaudited 4Q25 and FY25 net product sales of Aucatzyl (obe-cel, CD19 CAR-T), and provided a business update. $ 75m in FY25 Aucatzyl sales is in line with CSS ($ 75.9m) and ahead of our estimate of $ 72.5m. We believe this figure makes Aucatzyl's first year on the market a success, and we view FY26 guidance of $ 120-135m as within reach. Pipeline wise, we look forward to initial data from the phase 1 trial of Aucatzyl in the difficul...
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Wim Hoste
- Thibaut Voglimacci-Stephanopoli
- Martial Descoutures
- Martial Descoutures
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as o...
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025 Strasbourg, January 12, 2026 – 06:00 p.m. CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2025, the following resources were managed through the liquidity account: 304,479 shares€ 147,574.00 In the second half of 2025, a total of: Purchases348,958 shares€ 389,221.00988 market transactionsSales372,229 shares€ 424,419.001,278 market transactions It is recalled that when the liquidity program was initially established in 2016, the following resour...
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au...
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 31 décembre 2025 Strasbourg, le 12 janvier 2026 – 18h00 Au titre du contrat de liquidité confié par Transgene à Natixis Oddo BHF SCA, à la date du 31 décembre 2025, les moyens suivants figuraient au compte de liquidité : 304 479 titres Transgene147 574 € Au cours du second semestre 2025, il a été négocié un total de : Achat348 958 titres389 221 €988 transactionsVente372 229 titres424 419 €1 278 transactions Il est rappelé que lors de la mise en place du programme de liquidité en 2016, les moyens suivan...
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter an...
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus anticipates full year 2026 AUCATZYL® net product revenue of $120 million to $135 millionIndependent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Focus for 2026 is: Driving AUCATZYL®...
BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Upda...
BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026 2026 soll für BioNTech ein Jahr mit zahlreichen wertrelevanten Meilensteinen (Katalysatoren) werden, unter anderem durch weitere Fortschritte bei Pipeline-Kandidaten, die sich bereits in der späten klinischen Entwicklung befinden und Immunmodulatoren, Antikörper-Wirkstoff-Konjugate sowie mRNA-Krebsimmuntherapien abdeckenZu den erwarteten Meilensteinen in der Onkologie zählen im Jahr 2026 sieben Datenveröffentlichungen aus der späten klinischen Entwicklung sow...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.